Plenary Session

Latest Episodes:

2.45 Viral Spread of SARS-CoV-2, Rationing Resources, "Evidence Fiasco", & Classical Hematology Chat Apr 01, 2020

Show notes

This week we discuss several recent articles on the novel coronavirus (SARS-CoV-2) and COVID-19, specifically Dr. Siddhartha Mukherjee's article on the history and science of humanity's history with viruses, Dr. Ezekiel Emanuel's essay on how to fairly allocate dwindling medical resources during this global pandemic, and Dr. John Ioannidis's article on the "evidence fiasco" that has been our response to COVID-19. We end the episode with a Classical Hematology Chat with Drs. Sven Olson and Joseph Shatzel. Dr. Mukherjee's article: https://www.newyorker.com/magazine/2020/04/06/how-does-the-coronavirus-behave-inside-a-patient Allocation of Medical Resources: doi.org/10.1056/NEJMsb2005114 Dr. Ioannidis's article: https://www.statnews.com/2020/03/17/a-fiasco-in-the-making-as-the-coronavirus-pandemic-takes-hold-we-are-making-decisions-without-reliable-data/ Back us on Patreon! www.patreon.com/plenarysession

2.44 ICU Management of COVID-19 with Dr. Benjamin Singer Mar 25, 2020

Show notes

This week we discuss management of COVID-19 in the intensive care unit with Dr. Benjamin Singer, a pulmonary and critical care physician at Northwestern University. We discuss medications, PPE, ventilators, and more! Back us on Patreon! www.patreon.com/plenarysession

2.43 BONUS! Novel Coronavirus and the COVID-19 Response in Oregon with Dr. John Townes Mar 18, 2020

Show notes

This bonus episode is an interview from March 16, 2020 with Dr. John Townes, the Interim Head for the Division of Infectious Disease and the Medical Director for Infection Prevention and Control here at Oregon Health & Science University. We talk about the novel coronavirus and how healthcare professionals are responding to the COVID-19 pandemic, with a focus on Oregon. Back us on Patreon! www.patreon.com/plenarysession

2.42 Quality-of-Life Measurement in Oncology, KnowYourTumor, & Question of the Week Mar 17, 2020

Show notes

This week we discuss two recent papers -- one we praise, one we condemn -- and then we turn to a question of the week with medical student Audrey Tran on self-improvement and "refining conviction". The first paper is titled "Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials" and the second is titled "Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial". Quality of Life Measurement: doi.org/10.1001/jamanetworkopen.2020.0363 KnowYourTumor: doi.org/10.1016/S1470-2045(20)30074-7 Vinay's new book, Malignant: www.amazon.com/Malignant-Policy-…cer/dp/1421437635 Back us on Patreon! www.patreon.com/plenarysession

2.41 BONUS! Clinical Trials Part 2: Crossover and Control Arms Mar 11, 2020

Show notes

This BONUS lecture was a talk given to the Hematology/Oncology fellows here at Oregon Health & Science University. It's part two of a three-part series on clinical trials. This talk is on clinical trial design, specifically crossover and control arms. Back us on Patreon! www.patreon.com/plenarysession

2.40 BEACON part 2, NALA, & Molecular Pathology and Next-Generation Sequencing with Dr. David Carr Mar 05, 2020

Show notes

This week we revisit BEACON! The authors of the BEACON study have responded to the Letter to the Editor our host Dr. Vinay Prasad submitted to the New England Journal of Medicine, and we share our thoughts on what they said. We then turn to the FDA's recent approval of neratinib in combination with capecitabine for HER2-positive breast cancer, based on the phase III NALA trial. Finally, we interview Dr. David Carr, a Molecular Pathology Fellow at UC San Diego, on his work in general and, specifically, next-generation sequencing. BEACON Letters to the Editor: www.nejm.org/doi/full/10.1056/NEJMoa1908075#article_letters NALA: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neratinib-metastatic-her2-positive-breast-cancer Vinay's new book, Malignant: www.amazon.com/Malignant-Policy-…cer/dp/1421437635 Back us on Patreon! www.patreon.com/plenarysession

2.39 Effectiveness of Newer-Generation Antidepressants with Dr. Michael Hengartner Feb 27, 2020

Show notes

Our guest this week is Dr. Michael Hengartner of the Zurich University of Applied Sciences. We interview him on his work studying the long-term consequences and effectiveness of newer-generation antidepressants - specifically focusing on selective serotonin reuptake inhibitors (SSRIs). Back us on Patreon! www.patreon.com/plenarysession

2.38 KEYNOTE-048, Academic Currency, & Trials in Low/Mid-Income Countries with Dr. Bishal Gyawali Feb 19, 2020

Show notes

We start this episode by diving deep into KEYNOTE-048, the randomized, open-label, phase 3 study of pembrolizumab alone or with chemotherapy v.s. cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC). We transition from there to a continued discussion on careerism in academia and how the motivation behind publishing papers should always stem from the drive to disseminate information, not from the drive to advance your own career. We end the episode with an interview with Dr. Bishal Gyawali of Queen's University in Kingston, Canada on his recent paper out in Nature Cancer on global oncology. Specifically, Dr. Gyawali addresses the need for conducting cancer clinical trials in low- and middle-income countries. KEYNOTE-048: doi.org/10.1016/S0140-6736(19)32591-7 Opportunities for Cancer Clinical Trials in LMIC: doi.org/10.1038/s43018-020-0030-x Vinay's new book, Malignant: www.amazon.com/Malignant-Policy-…cer/dp/1421437635 Back us on Patreon! www.patreon.com/plenarysession

2.37 Careerism, Presenting Abstracts, Twitter and the K-Index, & Classical Hematology Chat Feb 14, 2020

Show notes

We have a full slate for you this week! We discuss careerism in medicine, presenting abstracts at conferences, #MedTwitter, and Dr. Califf's opinions on the K-Index. We conclude the episode with our first-ever Classical Hematology Chat, featuring our host Dr. Vinay Prasad, Dr. Sven Olson, and Dr. Joseph Shatzel. The chat is on sickle cell disease. "A Perspective on the K-Index": doi.org/10.1016/j.jaccas.2020.01.003 Back us on Patreon! www.patreon.com/plenarysession

2.36 Thought Leaders, NELSON, & Reliance on P Values in Cancer Trials with Dr. Sam Rubinstein Feb 07, 2020

Show notes

This week we discuss the concept of "thought leaders" and we examine the conclusions about volume CT screening for lung cancer from the NELSON trial. We end with an interview with Dr. Sam Rubinstein, a hematology/oncology fellow at Vanderbilt University Medical Center, on his new paper published in JAMA Network Open titled "Indication of Measures of Uncertainty for Statistical Significance in Abstracts of Published Oncology Trials: A Systematic Review and Meta-analysis". NELSON: doi.org/10.1056/NEJMoa1911793 Measures of Uncertainty: doi.org/10.1001/jamanetworkopen.2019.17530 Back us on Patreon! www.patreon.com/plenarysession

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected